The headline is that Mounjaro sales doubled. The number that decides the next three years is that realized prices fell 13% worldwide while volume rose 60%. Lilly is now running a volume business inside a falling price environment, and while volume compounds faster than price erodes the arithmetic looks like a boom. It is the same arithmetic that has closed every previous drug class cycle, arriving earlier than usual and at far greater scale. Growth of 48% on a 13% price decline is not a contradiction. It is a countdown.

• The US price decline is understated on the face of the release. Reported US realized prices fell 3%. Two sentences later Lilly states that excluding adjustments to estimates for rebates and discounts, the decline would have been approximately 9%. That six point gap comes from an accounting true-up rather than anything commercial, and the guidance section concedes the first half also benefited from those same adjustments alongside sales-based milestones. Anyone modelling US net price off the reported 3% is modelling an artifact. Use nine.
• The 36% price decline outside the US is what national reimbursement costs. Mounjaro joined China’s NRDL in the first quarter, and ex-US volume then rose 113% while ex-US realized price fell 36%. That is the access trade in its purest published form, and it is the one every payer team should be modelling as incretins enter national formularies elsewhere. A listing is neither a win nor a loss on its own. It is a price paid for a volume, and the only question that matters is whether the elasticity holds once the initial pool of untreated patients has been worked through.
• Read the two guidance lines together rather than separately. Revenue guidance went up by three billion dollars and the top of the EPS range came down, from $37.00 to $36.50, because $3.03 a share of acquired in-process research and development outweighed $2.78 of underlying improvement. Lilly closed Orna, Ajax, Centessa and Kelonia inside the quarter, added three infectious disease businesses and an agreement for AtaiBeckley after it, and committed a further $4.5 billion to Indiana manufacturing. That is a company converting an unusually generous price environment into permanent capacity and pipeline while it still has one. Note which risk factor now sits in the release: the voluntary agreement with the US government on drug pricing and access. That is where the next leg of price comes from, and it will not be offset by an accrual adjustment.